Therefore, another objective of this study was to confirm whether the incretin secretion capacity, which is essential for the action of DPP4-inhibitors, is preserved in patients with DM1, and to evaluate the effect of DPP-4 inhibitors in patients with DM1 complicated by diabetes using CGM. Here, DPP4 is linked to myotonic dystrophy type 1.